SALT LAKE CITY, Oct. 06, 2017 (GLOBE NEWSWIRE) -- PolarityTE™, Inc. (NASDAQ:COOL) today announced the appointment of Maurice Nahabedian, MD, FACS ( as Chief Surgical Officer. Dr. Nahabedian is recognized throughout the world for his work in breast and abdominal wall reconstruction and holds numerous leadership positions in the field, including serving as Vice-Chairman of this year's meeting of the American Society of Plastic Surgeons at "Plastic Surgery The Meeting" in Orlando, FL from October 6-10, 2017 (, the largest meeting of Plastic Surgeons in the country. In addition, he will serve as Chairman of the meeting next year.
Dr. Maurice Nahabedian
Dr. Maurice Nahabedian

A photo accompanying this announcement is available at

"It's humbling to bring aboard yet another world class expert in plastic and reconstructive surgery with the addition of Dr. Maurice Nahabedian as our Chief Surgical Officer," stated Denver Lough, MD, PhD, Chairman, Chief Executive Officer, and Chief Scientific Officer of PolarityTE™. "Dr. Nahabedian has paved a path of clinical innovation in breast and abdominal wall reconstruction and aesthetic surgery over the past two decades, wholly recognized by the field in his numerous appointments to elite leadership roles in plastic and reconstructive surgery. His expertise will be invaluable as we develop our product pipeline, expanding into fat (AdiposeTE™) and muscle (MyoTE™) regeneration, in particular. Furthermore, the experience and perspective of Dr. Nahabedian in cosmetic surgery will bolster our Regenerative Aesthetics Division and in-process development of numerous aesthetic product derivatives from our core platform of skin, bone, fat, and muscle regeneration."

Lough continued, "Although we're excited to work with Dr. Nahabedian on all development fronts, it is uniquely intriguing to pursue integrative applications of our autologous homologous technology with current tissue products utilized in the areas of breast and abdominal wall reconstruction, especially given his long-standing working relationships with industry. Acellular dermal matrices have greatly advanced reconstructive surgery in the breast and abdomen, but we have envisioned taking those concepts to the next level with our regenerative platform technology."

Dr. Maurice Nahabedian commented, "I am honored to join the Polarity team as Chief Surgical Officer, and I look forward to bringing truly regenerative products to the diverse patient population in need of answers to difficult problems. Polarity's approach to tissue regeneration aligns with the principles of reconstructive surgery that have been time-tested and proven in clinical practice, while simultaneously supplementing those foundations with a unique take on regenerative medicine." Nahabedian continued, "Moreover, it is refreshing to work for a company in the field of life sciences and healthcare not only led by the innovator behind the technology, but also by individuals who understand the significance of and challenges presented by the problems they are attempting solve."

About Maurice Nahabedian, MD, FACSMaurice Nahabedian, MD, FACS is an attending plastic surgeon at the National Center for Plastic Surgery in Virginia and former Professor and Section Chief of Plastic Surgery at the MedStar Washington Hospital Center and the Vice Chairman of the Department of Plastic Surgery at the Georgetown University Hospital in Washington, DC. He completed his Plastic Surgery residency at the Johns Hopkins Hospital in 1995 and was on the plastic surgery faculty at Johns Hopkins from 1995 - 2005 before joining the faculty at Georgetown University in 2005. His clinical interests include all aspects of breast surgery and abdominal wall reconstruction. Dr. Nahabedian has been the chairman of 19 conferences throughout the United States that include the Santa Fe Breast and Body Contouring Symposium, Aesthetica, Dueling Perspectives in Aesthetic Surgery Symposium, Complications in Plastic Surgery Symposium, Breast Cancer Comprehensive Conference (BC3) and the Abdominal Wall Reconstruction Symposium. He is the current Vice Chairman of the annual meeting program and instructional course committee for the American Society of Plastic Surgeons and will be the Chairman for the 2018 meeting. Dr. Nahabedian has delivered over 1,000 lectures on topics related to breast surgery and abdominal wall reconstruction at various local, national, and international conferences. He has been a visiting professor at 86 hospitals and universities since 2004. Dr. Nahabedian has published over 200 scientific manuscripts, editorials, and discussions, as well as 64 book chapters. He has edited 7 textbooks on breast surgery and abdominal wall reconstruction.  Dr. Nahabedian has been the Breast Section Editor for the Journal of Plastic and Reconstructive Surgery since 2009 and is on the editorial board of 4 other surgery journals. Dr. Nahabedian is certified by the American Board of Plastic Surgery and is a member of the American Society of Plastic Surgeons, American Society for Aesthetic Plastic Surgery, American College of Surgeons, American Association of Plastic Surgeons, and the American Society for Reconstructive Microsurgery.

About PolarityTE™ PolarityTE™, Inc. is a regenerative medicine company, and the first to successfully regenerate full-thickness tissue. The Company's novel regenerative medicine platform and proprietary technology employs a patient's own cells for the healing of full-thickness, functionally-polarized tissues. If clinically successful, the PolarityTE™ platform will provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The PolarityTE™ platform leverages natural and biologically-sound principles which are readily adaptable to a wide spectrum of organ and tissue systems. This revolutionary technology, paired with the Company's world-renowned clinical advisory board, position PolarityTE™ to drastically change the field and future of translational regenerative medicine. More information can be found online at

Forward Looking StatementsCertain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company's ongoing compliance with the requirements of The NASDAQ Stock Market and the Company's ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.


Scott SantiamoRussoPartnersLLC (718) 344-5843

David SchullRussoPartnersLLC (858) 717-2310

Primary Logo